Multifocal Anaplastic Pancreatic Carcinoma Requiring Neoadjuvant Chemotherapy and Total Pancreatectomy: Report of a Case
Context Anaplastic pancreatic carcinoma is a rare tumor with poor survival. Data on surgical and medical therapies are currently limited to case reports and case series with small numbers. Case report We describe a case of multifocal anaplastic pancreatic carcinoma treated with neoadjuvant FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil and leucovorin) and total pancreatectomy with subsequent patient disease-free survival currently at 12 months. Discussion The goal for anaplastic pancreatic carcinoma treatment should continue to be complete surgical resection. Optimum chemotherapeutic options continue to be investigated.
Image: Foreign body giant cells.
Hamilton SR, Aaltonen LA eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive system. Lyon: IARC Press 2000; 221–230.
Paal E, Thompson DL, Frommelt RA, Przygodzki RM, Heffess CS. A Clinicopathologic and Immunohistochemical study of 35 Anaplastic Carcinomas of the Pancreas with Review of the Literature. Annals of Diagn Pathol. 2001 Jun 5(3):129-140.
Chadha MK, LeVea C, Javle M, Kuvshinoff B, Vijaykumar R, Iyer R. Anaplastic Pancreatic Carcinoma. A Case Report and Review of Literature. JOP (Online) 2004;5(6):512-515.
Strobel O, Hartwig W, Bergmann F, Hinz U, Hackert T, Grenacher L et al. Anaplastic Pancreatic Cancer: Presentation, Surgical Management and Outcome. Surgery. 2011 Feb 149(2):200-8.
Bergmann F et al. Expression of L1CAM, Cox-2, EGFR, c-KIT and Her2/neu in Anaplastic Pancreatic Cancer: Putative Therapeutic Targets? Histopathology. 2010 Mar;56(4): 440-448.
Hoorens et al. Undifferentiated Carcinoma of the Pancreas: Analysis of Intermediate Filament Profile and Ki-ras Mutations Provides Evidence of a Ductal Origin. J of Pathology 1998 May;185(1)53-60.
Yamaguchi K, et al. Pleomorphic Carcinoma of the Pancreas:Reappraisal of Surgical Resection. Am J Gastroenterology 1998;93:1151-1155.
Clark C, Graham R, Arun J, Harmsen W, Reid-Lombardo K. Clinical Outcomes for Anaplastic Pancreatic Cancer: A Population-Based Study. Journal of the American College of Surgeons 2012 Nov;215(5), 627-634.
Wakatsuki T et al. Complete Response of Anaplastic Pancreatic Carcinoma to Paclitaxel Treatment Selected by Chemosensitivity Testing. Int J Clin Oncol. 2010 June;15(3): 310-313.
O’Reilly EM. Refinement of Adjuvant Therapy for Pancreatic Cancer. JAMA 2010 Sep 8;304(10):1124-1125.
Shinagare AB, Ramaiya NH, Bellizzi AM, Mayer RJ. Locally advanced anaplastic pancreatic adenocarcinoma with initial response to FOLFIRINOX and rapid progression after five months. Pancreatology. 2012 Jan-Feb;12(1):35-8. doi: 10.1016/j.pan.2012.01.001. Epub 2012 Jan 3.
Conroy T et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med. 2011 May 12;364(19):1817-25.
Levy A et al. FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Starting Point for Questioning. Pancreas 2012 Aug;41(6):973-4.
Copyright (c) 2014 Teresa S Jones, Edward L Jones, Martine McManus, Raj Shah, Csaba Gajdos
This work is licensed under a Creative Commons Attribution 4.0 International License.As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.